A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Multiple Myeloma
Age: Between 18 years - 90 years
Gender: Male or Female

Other Inclusion Criteria:

1) Newly diagnosed and symptomatic multiple myeloma. 2) Subject is willing and able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.

You may not be eligible for this study if the following are true:

1) Subjects should not have received any prior systemic antimyeloma treatment for MM except for induction therapy as recommended by the study protocol. 2) Subjects has high risk for developing deep vein thrombosis (DVT) or pulmonary embolus (PE) and are unable or unwilling to undergo anti-thrombotic therapy (eg, aspirin) while on lenalidomide (induction or maintenance).